SIAT^® Immunogenicity Analysis Service for Infectious Disease

Overview Service Advantages FAQ Resources

Infectious diseases are induced by various different microorganisms, such as bacteria, fungi, viruses, and parasites. Immunogenicity refers to the ability of an antigen to cause the immune response, which greatly affects the design of safety evaluation programs for disease-relevant biological products. As a famous expert in the market of immunologic analysis, Creative Biolabs supports immune disorder studies across multiple in vitro platforms and provides immunogenicity testing services of infectious diseases by our exclusive Sensitive Immunogenicity Assessment Technology® (SIAT®) system. Our skillful scientists will work with global clients to optimize customized assessment packages based on specific therapeutic goals and timeline.

Overview

Infectious disease testing entered the microbiology laboratory many years ago. Since then, a growing number of detection systems have been developed to identify microorganisms’ antigens. When symptoms emerged, the specific microorganism needs to be confirmed for further diagnosis and treatment. Many different microorganisms can cause a given infection, like pneumonia may be triggered by bacteria, viruses, or rarely fungi. The treatment is different for each microorganism. The sustained improvement of conventional methods and the advancement of novel, modern methods are why immunogenicity analysis remains an integral detection branch of infectious disease testing.

Services

SPPL2A Membrane Protein Introduction

Antigens are molecules that can provoke an immune response in the body. Microorganisms have these antigens on their surface and inside them. Immunogenicity tests could be used to describe the strength or magnitude of immune responses. At Creative Biolabs, we accept samples derived from an area containing the microorganism suspected of causing an infection, including bacterial sputum culture, blood, urine, stool, and mucus from nose, throat, or genital parts. In particular, we offer a suite of analytical services for understanding immune responses and arrange stand-alone or combination assays necessary for accurately and reliably assessing immunogenicity. Our platforms including but not limited to:

Agglutination tests - In this test (e.g. latex agglutination), very small particles (e.g. bacteria,latex beads, gelatin particles) are coupled to a reagent antigen. The resulting particle complex is mixed with the sample. If the target antigen is present in the mixture, it cross-links the particles, producing measurable agglutination.
Enzyme immunoassays - This method utilizes antibodies linked to enzymes to detect antigens, including enzyme immunoassay (EIA) and enzyme-linked immunosorbent assay (ELISA). Because of high sensitivity, enzyme immunoassays are usually used for screening.
Modified Western blotting (WB) - The Western blot typically has high specificity but not sensitive as ELISA. Our team has developed technical modifications of WB, including line immunoassay (LIA), recombinant immunoblot assay (RIBA), and immunochromatographic assays.
Precipitation tests - It measures an antigen or antibody in the body fluid by the degree of visible precipitation of antigen-antibody complexes within a gel or in solution. We provide many types of precipitation tests, such as double diffusion (Ouchterlony), counterimmunoelectrophoresis (CIE), and so on.
Microarray Immunogenicity probing - The multi-array slide system is used to create numerous leak-proof minipads on the microarray slides with antigen-related samples. After testing, image analysis and data quantification are implemented by microarray image analysis software.

Advantages

Full range of services to support immunogenicity analysis of infectious diseases.
Varieties of samples can be tested, including bacterial sputum culture, blood, sputum, urine, mucus, etc.
Sample reports are available for all standard assay services.
Highly trained immunology specialists with pioneering immunogenicity expertise.

No single immunogenicity analysis is able to identify every microorganism, and analysis that works well for one microorganism may not work well for another. When a microorganism is identified, susceptibility tests can be performed to determine which drugs or treatments are most effective against it sooner. As a leading independent immunogenicity provider in the world, Creative Biolabs can help clients to choose the best option to assess the immunogenicity of infectious diseases using a comprehensive series of immunogenicity assays. Depending on the project requirement, our tests and analytical services can be deployed alone or in combination. For more information, please directly contact us or discuss with our experts today.

Other optional immunogenicity analysis services for immune-related diseases:

FAQ

What is immunogenicity analysis in the context of infectious diseases?
Immunogenicity analysis for infectious diseases involves evaluating the immune response elicited by vaccines or therapeutic agents aimed at preventing or treating infections. This analysis helps determine the effectiveness of these interventions in stimulating an immune response that can neutralize the pathogen and provide protection against the disease.
Why is immunogenicity important for infectious disease treatments and vaccines?
Immunogenicity directly impacts their efficacy. A robust immunogenic response ensures that the body can recognize and combat the infectious agent effectively. In vaccines, this response typically involves the production of antibodies and activation of T cells, which are essential for long-term immunity.
How is immunogenicity measured in the context of infectious diseases?
Immunogenicity in infectious diseases is measured using various assays that quantify immune responses, such as enzyme-linked immunosorbent assays (ELISA) for antibody detection, T-cell proliferation tests, and neutralization assays that assess the ability of immune responses to inhibit virus replication in vitro.
How can immunogenicity analysis inform the development of infectious disease vaccines?
Immunogenicity analysis is critical in vaccine development as it provides insights into how well a vaccine induces an immune response. This information helps in optimizing vaccine formulations, selecting the most effective adjuvants, and determining the appropriate dosing schedules to enhance vaccine efficacy.
How does immunogenicity differ between therapeutic agents and vaccines for infectious diseases?
Immunogenicity for therapeutic agents often focuses on minimizing unwanted immune responses that could reduce the effectiveness of treatment, such as the development of ADAs. In contrast, for vaccines, the goal is to maximize a protective immune response that can prevent infection.